Alzheimer; News from the web:

Today, we are living history: the U.S. Food and Drug Administration (FDA) granted traditional approval of lecanemab, sold under the brand name Leqembi, for the treatment of early-stage Alzheimer’s disease. This is the first traditional approval granted for an Alzheimer’s treatment that changes the underlying course of the disease. Learn more here.

In addition, the Centers for Medicare & Medicaid Services (CMS) announced it will cover the treatment through Medicare. Read our statement here.

Read all about it HERE

Alzheimer; News from the web:

The Alzheimer’s Association is disappointed by the topline Phase 3 data reported today by Genentech and Roche from the GRADUATE Phase 3 global clinical trials of gantenerumab. However, these results will contribute to our understanding of this devastating and fatal disease. Although the drug did not meet its primary endpoint, the trials further illustrate the relationship between removal of beta-amyloid and reduction of clinical decline.

Read all about it HERE

Alzheimer; News from the web:

Nose-picking is a habit that is generally seen as unpleasant, but harmless. However, research from Griffith University in Queensland, Australia, suggests that the activity might not be as risk-free as previously thought.

The research, published in Nature Scientific ReportsTrusted Source, shows that by damaging the nasal cavity in mice, bacteria can enter the brain through the olfactory nerve.

Read all about it HERE

Alzheimer; News from the web:

There’s a more sensitive, but less commonly used, screening test called the Montreal Cognitive Assessment (MoCA).

We explain how the MoCA test works, when it’s used, and how it’s similar to and different from the Mini Mental Status Exam (MMSE). See our link for today

Read all about it HERE